+815.5%
ASTS vs MRNA
+257.4%
+558.1%
-77.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.7% | -0.9% | +9.6% | +8.8% |
| 7D | +2.8% | -3.8% | +6.6% | +3.4% |
| 30D | -28.8% | +16.4% | -45.2% | -29.8% |
| 3M | -48.9% | +310.6% | -359.5% | -59.8% |
| 6M | -55.6% | +370.3% | -425.9% | -67.0% |
| YTD | -49.6% | +743.3% | -792.9% | -69.2% |
| 1Y | -46.1% | +841.7% | -887.7% | -68.0% |
| All | +815.5% | +257.4% | +558.1% | +401.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling